睿知中国疾病研究地图
候选清单0

即将招募胃癌I/II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer

ClinicalTrials.gov 上登记的一项胃癌开放试验,由中山大学附属第六医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方中山大学附属第六医院Sixth Affiliated Hospital of Sun Yat-sen University广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06871527,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Pathologically determined gastric or gastroesophageal junction adenocarcinoma;

    入选标准第 3 条

  3. Had a major surgical procedure (thoracotomy, or laparotomy , etc.) within 4 weeks prior to the first dose of study therapy;

    排除标准第 13 条

  4. Eastern Cooperation Oncology Group (ECOG) performance status of 0-1;

    入选标准第 2 条

  5. At least one measurable lesion according to RECIST version 1.1;

    入选标准第 6 条

  6. Pregnant or lactating women, or patients of childbearing age who refused contraception during the study period;

    排除标准第 16 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06871527,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. 18-75 years old (including 18 and 75 years old);
  2. Eastern Cooperation Oncology Group (ECOG) performance status of 0-1;
  3. Pathologically determined gastric or gastroesophageal junction adenocarcinoma;
  4. Advanced patients with radiographic confirmation of inoperable complete resection;
  5. No previous anti-tumor treatment for metastatic diseases;
  6. At least one measurable lesion according to RECIST version 1.1;
  7. Ability to take medications orally;
  8. No active bleeding;
  9. Adequate organ functions:
  10. Have fully understood the study and voluntarily signed the informed consent;

排除标准:Exclusion Criteria:

  1. Patients who had received any drug in the study protocol in the last year;
  2. Deficient mismatch repair (dMMR) or MSI-H detected by genetic test;
  3. HER2 positive(HER-2 3+, or HER-2 2+ and FISH+);
  4. Hypertension that could not be controlled by drugs before enrollment was defined as: systolic blood pressure ≥150 mmHg and/or diastolic blood pressure ≥90 mmHg;
  5. Patients with acute coronary syndromes (including myocardial infarction and unstable angina) received coronary angioplasty or stenting within 6 months before enrollment;
  6. Patients with massive pleural or peritoneal effusion requiring drainage;
  7. Patients with severe ECG abnormalities or heart diseases (such as cardiac insufficiency, myocardial infarction, angina pectoris) that affect clinical treatment;
  8. Severe lung diseases (such as interstitial pneumonia, pulmonary fibrosis, severe emphysema, etc.);
  9. Mental disorders or central nervous system diseases or brain metastases affecting clinical treatment;
  10. Patients with autoimmune diseases;
  11. Patients with grade 3 or higher bleeding within 4 weeks;
  12. Patients with a history of allergy to any drug, similar drug or vehicle in this study;
  13. Had a major surgical procedure (thoracotomy, or laparotomy , etc.) within 4 weeks prior to the first dose of study therapy;
  14. Patients with nonhealed wounds, ulcers, or fractures;
  15. Patients who required systemic corticosteroids (excluding temporary testing, prophylactic administration for anaphylaxis), or immunosuppressive agents or had received such agents within 14 days before enrollment;
  16. Pregnant or lactating women, or patients of childbearing age who refused contraception during the study period;
  17. Investigators believe that the patient has any other conditions that are not suitable for participating in the study.

引自 ClinicalTrials.gov, NCT06871527, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06871527,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06871527